Leads Biolabs' LBL-024: CDE Approved Pivotal Clinical Study for Potential First-in-Class Anti-PD-L1/4-1BB Bispecific Antibody
Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights has received approval to conduct the single-arm pivotal study for registration and market.